Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Nova Eye Medical Ltd

EYE.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Advanced Medical Equipment & Technology ·

Australia Micro Cap Analyst: BUY

Last Close

$0.10

▼ -6.45%

Market Cap $29.14M · Vol 259.92K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$29.14M

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

+44.86%

YoY

RSI (14)

58.33

Momentum

Beta

1.72

vs Market

52W High

$0.15

28.56% below

52W Low

$0.07

49.11% above

Volume

259.92K

Avg 278.68K

P/B

1.65

Price-to-book

ROE

-39.11%

Return on equity

Free Float

64.51%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Nova Eye Medical Ltd (EYE.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EYE.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.45%

+26.09%

+16.00%

-12.12%

YTD

+9.43%

-9.38%

-34.65%

-67.63%

Financials & Valuation

TTM · Annual

Total Revenue	$19.26M
Net Income	$-5,960,810.00
Revenue Growth (YoY)	+29.30%
Gross Margin	64.54%
Operating Margin	-30.70%
Net Profit Margin	-30.95%
ROE	-39.11%
ROA · ROIC	-32.13% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.93
P/B	1.65
P/FCF	N/A
EPS Growth	+44.86%
Outstanding Shares	284.88M

Technical Indicators

50-Day SMA	$0.09
200-Day SMA	$0.10
RSI (14)	58.33
Beta	1.72
52-Week High	$0.15
52-Week Low	$0.07

Volume Today	259.92K
Avg Daily Volume (30D)	278.68K
Relative Volume	0.93x
Volatility (10D)	63.08
Volatility (30D)	83.74
Free Float	64.51%

Analyst Consensus

BUY

Current Price $0.10

Mean Target $0.36

52W Low$0.07 52W High$0.15

Current

Target

$0.07 $0.15

Current Analyst target

+246.53% upside potential · 1 analysts

Identifiers

ExchangeASX

FIGIBBG001SFWR17

ISINAU0000094252

CountryAustralia

Sub-IndustryAdvanced Medical Equipment & Technology (NEC)

Earnings DateAug 25, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

TMO Thermo Fisher Scientific Inc -1.28% DHR Danaher Corp -0.71% ISRG Intuitive Surgical Inc -1.68% BSX Boston Scientific Corp +0.27% EW Edwards Lifesciences Corp -1.04%

Company Profile

Nova Eye Medical Limited is an Australia-based medical technology company that develops, manufactures, and sells a portfolio of proprietary ophthalmic treatment technologies and devices. The Company operates through two segments: AlphaRET, and Glaucoma surgical devices. The Company’s AlphaRET segment is responsible for the commercialization of the 2RT ophthalmic laser, which is a treatment to delay progression to late-stage age-related macular degeneration (AMD) for patients who have the disease in its intermediate stage. 2RT is a patented nano-pulse laser device that rejuvenates retinal structures compromised by AMD. The Glaucoma Surgical Devices segment includes the designing, manufacturing, marketing, and sale of the iTrack, iTrack Advance and the Molteno3 glaucoma surgical device. The Molteno3 glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma.